ALS Ltd Stock
€12.30
Your prediction
Pros and Cons of ALS Ltd in the next few years
Pros
Cons
Performance of ALS Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ALS Ltd | - | 0.000% | 0.000% | 37.430% | 37.430% | 62.914% | 106.723% |
| Seek Ltd | -0.760% | -0.752% | -3.650% | -2.941% | -2.941% | 3.125% | -25.843% |
| Downer EDI Ltd | -0.450% | 0.455% | 1.843% | 42.581% | 41.667% | 90.517% | 32.335% |
| Insperity Inc. | -1.210% | 1.227% | 10.000% | -55.102% | -54.483% | -68.868% | -51.825% |
News
North American Niobium and Critical Minerals Corp. Completes Phase 1 Fall Prospecting Program; Carbonatite and Pegmatite Targets Identified Across Québec Properties
- Completion of Fall 2025 Prospecting Program Across Seigneurie, Bardy, Blanchette and Sabot Properties
- Carbonatite Boulders and Pegmatite Zones Identified
- 262
Electromed Posts 17% Gain in Fiscal Q4
Electromed (NYSEMKT:ELMD), a medical device company specializing in airway clearance therapy, reported record financial results for the quarter and fiscal year ended August 26, 2025. The company’s
Clene Posts 70% Revenue Drop in Q2
Clene (NASDAQ:CLNN), a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases, released its second-quarter 2025 earnings on August 14, 2025. The most important


